-
Something wrong with this record ?
Is phased implementation of HPV testing and triage with dual staining the way to transform organized cytology screening
J. Sláma, V. Dvořák, M. Trnková, A. Skřivánek, K. Hrabcová, P. Ovesná, M. Nováčková
Language English Country England, Great Britain
Document type Journal Article
- MeSH
- Staining and Labeling MeSH
- Early Detection of Cancer MeSH
- DNA MeSH
- Adult MeSH
- Uterine Cervical Dysplasia * diagnosis MeSH
- Papillomavirus Infections * MeSH
- Humans MeSH
- Human papillomavirus 16 genetics MeSH
- Human papillomavirus 18 genetics MeSH
- Uterine Cervical Neoplasms * MeSH
- Papanicolaou Test MeSH
- Mass Screening MeSH
- Triage MeSH
- Vaginal Smears MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVE: The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women >30 years of age. METHODS: Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16/18 genotyping at 3-year intervals. All HPV 16/18-positive cases and/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16/18-positive cases and LSILs were graded using p16/Ki67 dual-stain cytology, and positive cases were sent for colposcopy. RESULTS: Overall, 2409 patients were included. After the first combined screening (year 'zero') visit, 7.4% of women were HPV-positive and 2.0% were HPV16/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year 'three'), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all P ≤ 0.001). CONCLUSION: The addition of HPV DNA testing with selective genotyping of HPV16/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.
Center for Outpatient Gynaecology and Primary Care Brno
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007004
- 003
- CZ-PrNML
- 005
- 20240423155641.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/CEJ.0000000000000844 $2 doi
- 035 __
- $a (PubMed)37751376
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sláma, Jiří $u Department of Obstetrics, Gynecology and Neonatology, General University Hospital, 1 Medical Faculty, Charles University, Prague
- 245 10
- $a Is phased implementation of HPV testing and triage with dual staining the way to transform organized cytology screening / $c J. Sláma, V. Dvořák, M. Trnková, A. Skřivánek, K. Hrabcová, P. Ovesná, M. Nováčková
- 520 9_
- $a OBJECTIVE: The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women >30 years of age. METHODS: Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16/18 genotyping at 3-year intervals. All HPV 16/18-positive cases and/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16/18-positive cases and LSILs were graded using p16/Ki67 dual-stain cytology, and positive cases were sent for colposcopy. RESULTS: Overall, 2409 patients were included. After the first combined screening (year 'zero') visit, 7.4% of women were HPV-positive and 2.0% were HPV16/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year 'three'), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all P ≤ 0.001). CONCLUSION: The addition of HPV DNA testing with selective genotyping of HPV16/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a dysplazie děložního hrdla $x diagnóza $7 D002578
- 650 12
- $a nádory děložního čípku $7 D002583
- 650 _2
- $a lidský papilomavirus 16 $x genetika $7 D052162
- 650 12
- $a infekce papilomavirem $7 D030361
- 650 _2
- $a třídění pacientů $7 D014218
- 650 _2
- $a lidský papilomavirus 18 $x genetika $7 D052161
- 650 _2
- $a plošný screening $7 D008403
- 650 _2
- $a Papanicolaouův test $7 D065006
- 650 _2
- $a DNA $7 D004247
- 650 _2
- $a barvení a značení $7 D013194
- 650 _2
- $a časná detekce nádoru $7 D055088
- 650 _2
- $a vaginální stěr $7 D014626
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dvořák, Vladimír $u Center for Outpatient Gynaecology and Primary Care, Brno
- 700 1_
- $a Trnková, Markéta $u Unilabs Pathology, Prague
- 700 1_
- $a Skřivánek, Aleš $u G-Center, Olomouc
- 700 1_
- $a Hrabcová, Karolína $u Institute of Biostatistics and Analyses, Brno, Czech Republic
- 700 1_
- $a Ovesná, Petra $u Institute of Biostatistics and Analyses, Brno, Czech Republic
- 700 1_
- $a Nováčková, Martina $u Institute of Biostatistics and Analyses, Brno, Czech Republic
- 773 0_
- $w MED00001604 $t European journal of cancer prevention $x 1473-5709 $g Roč. 33, č. 2 (2024), s. 168-176
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37751376 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155637 $b ABA008
- 999 __
- $a ok $b bmc $g 2081166 $s 1216771
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 33 $c 2 $d 168-176 $e 20230921 $i 1473-5709 $m European journal of cancer prevention $n Eur J Cancer Prev $x MED00001604
- LZP __
- $a Pubmed-20240412
